Ting-ting Chang
TPQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Xaliproden improves diabetic kidney disease through JNK-mediated renal tubular protection.
Journal: Biochemical pharmacology
Published: January 28, 2026
Revealing unseen wounds: a cluster analysis of psychological and pandemic-driven factors associated with self-injury among global students.
Journal: BMC psychology
Published: July 17, 2025
FABP4 inhibition protects renal tubular cells and ameliorates renal inflammation in diabetic kidney disease.
Journal: Biochemical pharmacology
Published: November 08, 2024
Fatty acid binding protein 3 activates endothelial adhesion of circulating monocytes and impairs endothelial angiogenesis.
Journal: British journal of pharmacology
Published: June 08, 2024
CXCL5 inhibition improves kidney function by protecting renal tubular epithelial cells in diabetic kidney disease.
Journal: Clinical immunology (Orlando, Fla.)
Published: March 20, 2024
Novel prognostic impact and cell specific role of endocan in patients with coronary artery disease.
Journal: Clinical research in cardiology : official journal of the German Cardiac Society
Published: February 14, 2024
Soluble tumor necrosis factor receptor type 1 is an alternative marker of urinary albumin-creatinine ratio and estimated glomerular filtration rate for predicting the decline of renal function in subjects with type 2 diabetes mellitus.
Journal: Clinica chimica acta; international journal of clinical chemistry
Published: January 03, 2024
Mechanistic role of CXCL5 in cardiovascular disease, diabetes mellitus, and kidney disease.
Journal: Life sciences
Published: June 26, 2023
GMI, a fungal immunomodulatory protein, ameliorates SARS-CoV-2 envelope protein-induced inflammation in macrophages via inhibition of MAPK pathway.
Journal: International journal of biological macromolecules
Published: March 10, 2023
Macrophage inflammatory protein-1β as a novel therapeutic target for renal protection in diabetic kidney disease.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: January 05, 2023
Potential Impacts of Hydralazine as a Novel Antioxidant on Cardiovascular and Renal Disease-Beyond Vasodilation and Blood Pressure Lowering.
Journal: Antioxidants (Basel, Switzerland)
Published: October 02, 2022
CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease.
Journal: Cardiovascular diabetology
Published: August 01, 2022
Last Updated: 09/26/2026